Company intelligence / Profile preview

scPharmaceuticals Inc.

Burlington, Massachusetts, United Statesir.scpharma.com ↗

Ownership: Public · SCPH
Development stage: Commercial

Overview

scPharmaceuticals has successfully commercialized FUROSCIX (furosemide injection), which received FDA approval for heart failure in 2022 and expanded indication for chronic kidney disease in March 2025. The company reported $36.3 million in revenue for full year 2024, with approximately 41,000 FUROSCIX doses filled in 2024.

Therapeutic areas: CardiovascularNephrology
Modalities: Drug-device combinations
Industry: Biotech

Drug pipeline

2 assets

SCP-111

1 more asset in the full pipeline.

Request access →

Partnerships

Late-stage cardiovascular and renal R&D companies

Financials

Market cap: $302.2M
Total revenue: $16M
Enterprise value: $314.8M

Beyond the preview

Go deeper on scPharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on scPharmaceuticals Inc..

Explore the full profile